Blue Dream lab report

California had the highest 20%+ share in this state comparison, while the full Blue Dream flower set sits near even odds at 20%: 49% of 2,118 tests were at that cutoff or higher, with 7.8% at or above 25% and 0.3% at or above 30%.¹ Its median was 19.96%.¹

The state split is wide: 88% of California tests met or exceeded 20% (83 tests, median 25.38%), compared with 7.8% in Hawaii (64 tests, median 17.47%).¹ The gap reflects each market's growers, labs and testing rules, not only the plant.

Yes, but rarely: Blue Dream reached the highest single claim, ILGM's 29%, in only 0.6% of tests, while three of the four single figures we checked sit higher than the lab median of 19.96%.^1,4

At the low end, Humboldt Seed Organization's 19% was met or topped by 61% of tests.^1,5 The published ranges covered more tests: the 15–27% range from Weedmaps contained 93%, while the 17–24% range from AllBud contained 69%.^1,6,7

These figures are not batch documents; for a purchase, the relevant lab record is the certificate of analysis for that batch.

The terpene Blue Dream has most often is β-myrcene: it led 68% of 484 flower tests that included individual terpene results, ahead of α-pinene at 24% and β-caryophyllene at 6.6%.¹ That is a clear lead but not a lock, because α-pinene still leads a minority of tests.¹

Leafly names myrcene as dominant, and the lab count agrees: β-myrcene led 68%.^1,2

The terpene sample is concentrated in Nevada: 405 of 484 tests came from that state, so the shares mainly describe Nevada flower.¹

Mimosa, Strawberry Cough and Green Crack are the strains with typical terpene mixes most similar to Blue Dream, scoring 82%, 81% and 73%; the least similar in the comparison pool was Tropicana Cherry at 41%.¹ The nearest three all lead with β-myrcene, while Tropicana Cherry leads with β-caryophyllene.¹

For the match score, we first take the median amount of each of eight terpenes and express those values as parts of their combined total; the overlap is the shared part of two profiles, and identical mixes score 100.¹ A strain needs at least 30 individual-terpene tests to enter the pool, and this compares lab chemistry only, not how Blue Dream will feel.¹

Among qualifying strains, Blue Dream ranks 33rd of 52 strains by median total THC, a middle-third position at 19.96%, between Runtz Cake (20.00%) and Pineapple Express (19.80%).¹ Its share at 25% or more was 7.8%, ranking 37th.¹

Its middle half is comparatively tight at 17.62%–22.37%, a span of 4.75 points, ranked 16th narrowest among 52 strains with enough tests.¹ That makes results under the Blue Dream name more consistent than most strains in this dataset.¹

For flower batches spanning growers and state markets, inside Michigan, labs with at least 20 tests differed by 5.72 points, and the broader Blue Dream lab spread ran across 21 such labs from 15.07% at Lab I in Michigan (60 tests) to 24.93% at Lab G in California (64), a gap of 9.86 points.¹

The difference persists inside Michigan: the eight labs there with at least 20 tests ranged from 15.07% to 20.79%, a gap of 5.72 points.¹

Because each lab receives flower from different growers, these spreads do not prove a lab reads high; they show how grower mix and lab choice can move the label number. Lab names are masked here, with Lab A assigned to the lab with the largest count; the downloadable test file includes the real lab names.

Yes: across 733 paired Blue Dream tests, the high-THC third at 21.81% or more carried a 2.07% median total-terpene level, while the low-THC third at 18.82% or less carried 1.24%; the terpene median gap was 0.83 points, and the same direction appeared in three of three states with enough paired tests.¹

State by state, the higher-THC side also had the higher terpene median in three of three places with enough paired tests: Nevada up, Maryland up and California up.¹ As a weight percentage, total terpenes are aroma-compound measurements only; they do not describe effects.

Not in Nevada: Blue Dream moved from 19.39% in 2020 to 18.09% in 2023, −1.30 points, even though the overall median rose from 18.30% in 2017 (31 tests) to 23.21% in 2024 (50), a change of +4.91 points.¹

Inside Nevada, the direction flips: 2020 recorded 19.39%, while 2023 recorded 18.09%, −1.30 points.¹ The overall rise depends partly on which states contributed tests in each year.¹ We omit any year below 20 tests.¹

Concentrates account for 25% of exact-name Blue Dream lab records, while flower still makes up 65% (2,473 of 3,820 records), with 4.7% shake and trim and 3.7% pre-rolls.¹ This site's THC and terpene calculations use flower only.

Longer names are kept out: 775 results included Blue Dream plus extra words, 17% of all results with the name in them, led by “Santa Cruz Blue Dream” (84), “Super Blue Dream” (31) and “Blue Dream OG” (28).¹ They may point to different products or plants, so we exclude them under our name-matching rules.

Yes: in the Oct 3, 2026 Weedmaps snapshot, Blue Dream ranked 2nd among 58 tracked strains, with 850 store listings for its flower on menus no farther than 50 miles from each market center and listings in 23 of 27 markets.³

By market, the Blue Dream exact-eighth median versus the same-menu strain median was: Los Angeles, CA, $25.00 versus $25.00; New York, NY, $41.05 versus $35.70; Seattle, WA, $25.00 versus $30.00; Detroit, MI, $17.00 versus $16.00; Oklahoma City, OK, $20.00 versus $17.04; Portland, ME, $25.00 versus $25.00; Denver, CO, $17.50 versus $20.16; Newark, NJ, $45.00 versus $42.88; Chicago, IL, $35.50 versus $43.20; Portland, OR, $29.17 versus $25.00; and Boston, MA, $25.00 versus $30.00.³ It came in lower than the same-menu comparison median in four of eleven markets, so pricing was mixed.³